Literature DB >> 31131314

Does cancer cell-expressed SLAMF7 impact on CD47-mediated phagocytosis?

Renee Bouwstra1, Tom van Meerten1, Edwin Bremer1.   

Abstract

Innate immune checkpoint CD47 has emerged as a prominent target for cancer immunotherapy and defining biomarkers predictive of response will be a crucial step towards clinical implementation. Hereto, we investigated the importance of a previously reported requisite for SLAM family member 7(SLAMF7) expression on cancer cell phagocytosis for effective CD47 antibody therapy.

Entities:  

Keywords:  CD47; DLBCL; SLAMF7; phagocytosis

Year:  2019        PMID： 31131314      PMCID： PMC6512920          DOI： 10.1080/23723556.2019.1600349

Source DB:  PubMed          Journal:  Mol Cell Oncol        ISSN： 2372-3556


  7 in total

1.  Calreticulin is the dominant pro-phagocytic signal on multiple human cancers and is counterbalanced by CD47.

Authors:  Mark P Chao; Siddhartha Jaiswal; Rachel Weissman-Tsukamoto; Ash A Alizadeh; Andrew J Gentles; Jens Volkmer; Kipp Weiskopf; Stephen B Willingham; Tal Raveh; Christopher Y Park; Ravindra Majeti; Irving L Weissman
Journal:  Sci Transl Med       Date:  2010-12-22       Impact factor: 17.956

2.  SLAMF7 is critical for phagocytosis of haematopoietic tumour cells via Mac-1 integrin.

Authors:  Jun Chen; Ming-Chao Zhong; Huaijian Guo; Dominique Davidson; Sabrin Mishel; Yan Lu; Inmoo Rhee; Luis-Alberto Pérez-Quintero; Shaohua Zhang; Mario-Ernesto Cruz-Munoz; Ning Wu; Donald C Vinh; Meenal Sinha; Virginie Calderon; Clifford A Lowell; Jayne S Danska; André Veillette
Journal:  Nature       Date:  2017-04-19       Impact factor: 49.962

3.  Engagement of MHC class I by the inhibitory receptor LILRB1 suppresses macrophages and is a target of cancer immunotherapy.

Authors:  Amira A Barkal; Kipp Weiskopf; Kevin S Kao; Sydney R Gordon; Benyamin Rosental; Ying Y Yiu; Benson M George; Maxim Markovic; Nan G Ring; Jonathan M Tsai; Kelly M McKenna; Po Yi Ho; Robin Z Cheng; James Y Chen; Layla J Barkal; Aaron M Ring; Irving L Weissman; Roy L Maute
Journal:  Nat Immunol       Date:  2017-11-27       Impact factor: 25.606

4.  Anti-CD47 antibody synergizes with rituximab to promote phagocytosis and eradicate non-Hodgkin lymphoma.

Authors:  Mark P Chao; Ash A Alizadeh; Chad Tang; June H Myklebust; Bindu Varghese; Saar Gill; Max Jan; Adriel C Cha; Charles K Chan; Brent T Tan; Christopher Y Park; Feifei Zhao; Holbrook E Kohrt; Raquel Malumbres; Javier Briones; Randy D Gascoyne; Izidore S Lossos; Ronald Levy; Irving L Weissman; Ravindra Majeti
Journal:  Cell       Date:  2010-09-03       Impact factor: 41.582

5.  CD47-blocking immunotherapies stimulate macrophage-mediated destruction of small-cell lung cancer.

Authors:  Kipp Weiskopf; Nadine S Jahchan; Peter J Schnorr; Sandra Cristea; Aaron M Ring; Roy L Maute; Anne K Volkmer; Jens-Peter Volkmer; Jie Liu; Jing Shan Lim; Dian Yang; Garrett Seitz; Thuyen Nguyen; Di Wu; Kevin Jude; Heather Guerston; Amira Barkal; Francesca Trapani; Julie George; John T Poirier; Eric E Gardner; Linde A Miles; Elisa de Stanchina; Shane M Lofgren; Hannes Vogel; Monte M Winslow; Caroline Dive; Roman K Thomas; Charles M Rudin; Matt van de Rijn; Ravindra Majeti; K Christopher Garcia; Irving L Weissman; Julien Sage
Journal:  J Clin Invest       Date:  2016-06-13       Impact factor: 14.808

6.  CD47 Blockade by Hu5F9-G4 and Rituximab in Non-Hodgkin's Lymphoma.

Authors:  Ranjana Advani; Ian Flinn; Leslie Popplewell; Andres Forero; Nancy L Bartlett; Nilanjan Ghosh; Justin Kline; Mark Roschewski; Ann LaCasce; Graham P Collins; Thu Tran; Judith Lynn; James Y Chen; Jens-Peter Volkmer; Balaji Agoram; Jie Huang; Ravindra Majeti; Irving L Weissman; Chris H Takimoto; Mark P Chao; Sonali M Smith
Journal:  N Engl J Med       Date:  2018-11-01       Impact factor: 91.245

7.  Cancer cell-expressed SLAMF7 is not required for CD47-mediated phagocytosis.

Authors:  Yuan He; Renee Bouwstra; Valerie R Wiersma; Mathilde de Jong; Harm Jan Lourens; Rudolf Fehrmann; Marco de Bruyn; Emanuele Ammatuna; Gerwin Huls; Tom van Meerten; Edwin Bremer
Journal:  Nat Commun       Date:  2019-02-01       Impact factor: 14.919
  7 in total
  2 in total

Review 1.  Recent updates on CAR T clinical trials for multiple myeloma.

Authors:  Quande Lin; Juanjuan Zhao; Yongping Song; Delong Liu
Journal:  Mol Cancer       Date:  2019-11-05       Impact factor: 27.401

Review 2.  Targeting Myeloid Checkpoint Molecules in Combination With Antibody Therapy: A Novel Anti-Cancer Strategy With IgA Antibodies?

Authors:  Chilam Chan; Marta Lustig; Niklas Baumann; Thomas Valerius; Geert van Tetering; Jeanette H W Leusen
Journal:  Front Immunol       Date:  2022-07-05       Impact factor: 8.786
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.